Boehringer Ingelheim (France)

Early versus delayed or no empagliflozin initiation after hospitalisation for heart failure in the United States: A target trial emulation

BACKGROUND: Sodium-glucose cotransporter-2 inhibitors (SGLT2is) are a foundational therapy for heart failure (HF), yet initiation is frequently delayed in clinical practice. Evidence comparing outcomes associated with early versus delayed or no initiation following hospitalisatio...

Timing of antifibrotic therapy and prognosis in idiopathic pulmonary fibrosis: real-world evidence from the French Colibri-ILD SNDS database

According to the French 2022 National guideline, antifibrotic therapy should be initiated as soon as a diagnosis of idiopathic pulmonary fibrosis (IPF) is made, taking into account the individual assessment of the expected benefit and risks of treatment. However, in practice, tre...

Recent Advancesin Nonprecious Metal Catalysis

Abstract As part of a precompetitive alliance, Boehringer Ingelheim, Pfizer, and AbbVie publish a quarterly review series dedicated to recent advances in nonprecious metal catalysis (NPMC). By informing synthetic chemists about noteworthy developments in NPMC, these reviews aim t...